Initial Filing of Beneficial Ownership by David E. Lazar

David E. Lazar, Co-Chief Executive Officer of Indaptus Therapeutics, Inc., has filed an initial report of beneficial ownership (Form 3) detailing transactions on December 22, 2025. Lazar acquired 300,000 shares of Series AA Convertible Preferred Stock and 700,000 shares of Series AAA Convertible Preferred Stock, both at $6.00 per share. The Series AA Preferred Stock is convertible into 6,000,000 shares of Common Stock, and the Series AAA Preferred Stock is convertible into 105,000,000 shares of Common Stock, subject to ownership limitations. The Preferred Stock is perpetual and convertible at the holder's option without additional consideration. As of the filing date, Lazar directly holds 0 shares of Common Stock, as indicated by footnote F1.